Five-year overall survival rates for medulloblastoma range from 40 to 98%, depending on molecular subtype (Hovestadt et al., 2020), with MYC-amplified Group 3 medulloblastoma associated with very poor survival rates. Here, MYC is linked to medulloblastoma.